Pro-arrhythmic potential of oral antihistamines (H1) : combining adverse event reports with drug utilization data across Europe

Tools

Poluzzi, Elisabetta and Raschi, Emanuel and Godman, Brian and Koci, Ariola and Moretti, Ugo and Kalaba, Marija and Wettermark, Bjorn and Sturkenboom, Miriam and De Ponti, Fabrizio (2015) Pro-arrhythmic potential of oral antihistamines (H1) : combining adverse event reports with drug utilization data across Europe. PLOS One, 10 (3). e0119551. ISSN 1932-6203 (https://doi.org/10.1371/journal.pone.0119551)

[thumbnail of Poluzzi-etal-PlosOne-2015-Pro-arrhythmic-potential-of-oral-antihistamines]
Preview
 Text. Filename: Poluzzi_etal_PlosOne_2015_Pro_arrhythmic_potential_of_oral_antihistamines.pdf
Final Published Version
License: Creative Commons Attribution 4.0 logo
Download (360kB)| Preview

Abstract

Background. There is appreciable utilisation of antihistamines (H1) in European countries, either prescribed by physician and purchased by patients for self-medication. Terfenadine and astemizole underwent regulatory restrictions in ’90 because of their cardiac toxicity, but only scarce clinical data are available on other antihistamines. Aim. To investigate the pro-arrhythmic potential of antihistamines by combining safety reports of the FDA Adverse Event Reporting System (FAERS) with drug utilization data from 13 European Countries. Methods. We identified signals of antihistamine arrhythmogenic potential by analyzing FAERS database for all cases of Torsades de Pointes (TdP), QT abnormalities (QTabn), ventricular arrhythmia (VA) and sudden cardiac death/cardiac arrest (SCD/CA). Number of cases ≥3 and disproportionality were used to define alert signals: TdP and QTabn identified stronger signals, whereas SCD/CA identified weaker signals. Drug utilization data from 2005 to 2010 were collected from administrative databases through health authorities and insurance.Results. Antihistamines were reported in 109 cases of TdP/QT prolongation, 278 VA and 610 SCD/CA. Five agents resulted in stronger signals (cetirizine, desloratadine, diphenhydramine, fexofenadine, loratadine) and 6 in weaker signals (alimemazine, carbinoxamine, cyclizine, cyproeptadine, dexchlorpheniramine and doxylamine). Exposure to antihistamines with stronger signal was markedly different across European countries and was at least 40% in each Country. Cetirizine was >29 Defined Daily Doses per 1000 inhabitants per day (DID) in Norway, desloratadine >11 DID in France and loratadine >9 DID in Sweden and Croatia. Drugs with weaker signals accounted for no more than 10% (in Sweden) and in most European countries their use was negligible.Conclusions. Some second-generation antihistamines are associated with signal of torsadogenicity and largely used in most European countries. Although confirmation by analytical studies is required, regulators and clinicians should consider risk-minimisation activities. Also antihistamines without signal but with peculiar use in a few Countries (e.g., levocetirizine) or with increasing consumption (e.g., rupatadine) deserve careful surveillance.

CORE (COnnecting REpositories)